Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Heparin Versus Saline Locking of Peripheral Venous Catheters (HESAL)

16. november 2026 oppdatert av: Consorci Sanitari de l'Alt Penedès i Garraf

Heparin Versus Saline Locking of Peripheral Venous Catheters: a Multicenter Retrospective Cohort Study

The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:

  • Is the percentage of blocked peripheral venous catheters higher in patients whose catheters are locked with saline than in those whose catheters are locked with heparin?
  • Do the rates of other catheter-related complications (phlebitis, catheter-related bloodstream infection, extravasation, and leakage at the insertion site) differ between the two groups?
  • Which clinical and drug-related factors are associated with catheter blockage?

Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.

The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.

The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.

Studietype

Observasjonsmessig

Registrering (Antatt)

3450

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Noemí Casaponsa
  • Telefonnummer: 43197 0034938960025
  • E-post: recerca@csapg.cat

Studiesteder

    • Barcelona
      • Sant Pere de Ribes, Barcelona, Spania, 08810
        • Hospital Residència Sant Camil
        • Ta kontakt med:
        • Hovedetterforsker:
          • Esther Moreno Rubio
      • Vilafranca del Penedès, Barcelona, Spania, 08720
        • Hospital Comarcal de l'Alt Penedès
        • Ta kontakt med:
        • Hovedetterforsker:
          • Esther Moreno Rubio

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.

Beskrivelse

Inclusion Criteria:

  • Admitted to Hospital Residència Sant Camil (CSAPG) or Hospital Comarcal de l'Alt Penedès (CSAPG) during the study period
  • At least one peripheral venous catheter for intermittent treatment, not inserted in a medical emergency
  • Aged 18 years or older

Exclusion Criteria:

  • Known allergy to heparin
  • Treatment with systemic unfractionated sodium heparin
  • Dialysis
  • Venous catheter used only for diagnostic tests
  • Venous catheter used only for transfusion of blood products
  • Participation in another clinical study with drugs or procedures that may affect catheter patency
  • Severe heparin-induced thrombocytopenia in recent months
  • Uncontrolled active bleeding during admission
  • Cerebral aneurysm or dissecting aortic aneurysm, except in association with corrective surgery
  • Confirmed or suspected cerebrovascular hemorrhage
  • Severe uncontrolled hypertension
  • Severe coagulation disorders: platelets below 30,000/µL, prothrombin time ratio above 1.7, or activated partial thromboplastin time ratio above 1.7

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Cohort A: saline locking
Cohort B: heparin locking

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of blocked peripheral venous catheters
Tidsramme: Hospital discharge, up to 12 weeks

Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion).

Hospital discharge, up to 12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

6. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

IPD-delingstidsramme

After publication of main results of the study.

Tilgangskriterier for IPD-deling

IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere